On Thursday, AstraZeneca Plc (NYSE:PLC) and Amgen Inc. (NASDAQ:AMGN) shared topline data from the Phase 3 CROSSING trial of Tezspire (tezepelumab) administered subcutaneously every four weeks, compared to placebo in symptomatic and histologically active eosinophilic esophagitis (EoE) patients.
Tezspire Shows Significant Improvements
EoE is a chronic, immune-mediated inflammatory disease where white blood cells called eosinophils build up in the lining of the esophagus (a muscular tube that connects the throat to the stomach to transport food and liquid), causing damage and difficulty swallowing.
EoE affects more than 470,000 people in the U.S., with the prevalence increasing fivefold since 2009.
Data showed that Tezspire demonstrated statistically significant and clinically meaningful improvements across both co-primary and all key secondary endpoints at week 24, which were sustained through week 52 in both doses tested.
